Abstract
There have been recent proposals advocating the use of additive gene-environment interaction instead of the widely used multiplicative scale, as a more relevant public health measure. Using gene-environment independence enhances statistical power for testing multiplicative interaction in case-control studies. However, under departure from this assumption, substantial bias in the estimates and inflated type I error in the corresponding tests can occur. In this paper, we extend the empirical Bayes (EB) approach previously developed for multiplicative interaction, which trades off between bias and efficiency in a data-adaptive way, to the additive scale. An EB estimator of the relative excess risk due to interaction is derived, and the corresponding Wald test is proposed with a general regression setting under a retrospective likelihood framework. We study the impact of gene-environment association on the resultant test with case-control data. Our simulation studies suggest that the EB approach uses the gene-environment independence assumption in a data-adaptive way and provides a gain in power compared with the standard logistic regression analysis and better control of type I error when compared with the analysis assuming gene-environment independence. We illustrate the methods with data from the Ovarian Cancer Association Consortium.
Original language | English (US) |
---|---|
Pages (from-to) | 366-377 |
Number of pages | 12 |
Journal | American journal of epidemiology |
Volume | 187 |
Issue number | 2 |
DOIs | |
State | Published - Feb 1 2018 |
Keywords
- bias-variance tradeoff
- effect modification
- empirical Bayes estimation
- genetic risk score
- relative excess risk
- shrinkage
ASJC Scopus subject areas
- Epidemiology
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. / for the Ovarian Cancer Association Consortium.
In: American journal of epidemiology, Vol. 187, No. 2, 01.02.2018, p. 366-377.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence
AU - for the Ovarian Cancer Association Consortium
AU - Liu, Gang
AU - Mukherjee, Bhramar
AU - Lee, Seunggeun
AU - Lee, Alice W.
AU - Wu, Anna H.
AU - Bandera, Elisa V.
AU - Jensen, Allan
AU - Rossing, Mary Anne
AU - Moysich, Kirsten B.
AU - Chang-Claude, Jenny
AU - Doherty, Jennifer A.
AU - Gentry-Maharaj, Aleksandra
AU - Kiemeney, Lambertus
AU - Gayther, Simon A.
AU - Modugno, Francesmary
AU - Massuger, Leon
AU - Goode, Ellen L.
AU - Fridley, Brooke L.
AU - Terry, Kathryn L.
AU - Cramer, Daniel W.
AU - Ramus, Susan J.
AU - Anton-Culver, Hoda
AU - Ziogas, Argyrios
AU - Tyrer, Jonathan P.
AU - Schildkraut, Joellen M.
AU - Kjaer, Susanne K.
AU - Webb, Penelope M.
AU - Ness, Roberta B.
AU - Menon, Usha
AU - Berchuck, Andrew
AU - Pharoah, Paul D.
AU - Risch, Harvey
AU - Pearce, Celeste Leigh
N1 - Funding Information: Anna H. Wu, Simon A. Gayther, Celeste Leigh Pearce); Cancer Prevention and Control Research Program, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey (Elisa V. Bandera); Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark (Allan Jensen, Susanne K. Kjaer); Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington (Mary Anne Rossing); Department of Epidemiology, School of Public Health, University of Washington, Seattle, Washington (Mary Anne Rossing); Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York (Kirsten B. Moysich); Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany (Jenny Chang-Claude); University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (Jenny Chang-Claude); Department of Epidemiology, Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, New Hampshire (Jennifer A. Doherty); Gynaecological Cancer Research Centre, Women’s Cancer, Institute for Women’s Health, University College London, London, United Kingdom (Aleksandra Gentry-Maharaj, Usha Menon); Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, the Netherlands (Lambertus Kiemeney); Department of Obstetrics, Gynecology, and Reproductive Sciences, Division of Gynecologic Oncology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania (Francesmary Modugno); Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania (Francesmary Modugno); Womens Cancer Research Program, Magee-Womens Research Institute and University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania (Francesmary Modugno); Department of Obstetrics and Gynaecology, Radboud University Medical Center, Nijmegen, the Netherlands (Leon Massuger); Department of Health Sciences Research, Division of Epidemiology, Mayo Clinic, Rochester, Minnesota (Ellen L. Goode); University of Kansas Medical Center, Kansas City, Kansas (Brooke L. Fridley); Obstetrics and Gynecology Center, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts (Kathryn L. Terry, Daniel W. Cramer); Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts (Kathryn L. Terry, Daniel W. Cramer); School of Women’s and Children’s Health, University of New South Wales, Sydney, New South Wales, Australia (Susan J. Ramus); Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia (Susan J. Ramus); Genetic Epidemiology Research Institute, Center for Cancer Genetics Research and Prevention, School of Medicine, University of California, Irvine, Irvine, California (Hoda Anton-Culver, Argyrios Ziogas); Strangeways Research Laboratory, Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom (Jonathan P. Tyrer, Paul D. Pharoah); Department of Public Health Sciences, School of Medicine, University of Virginia, Charlottesville, Virginia (Joellen M. Schildkraut); Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Susanne K. Kjaer); QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia (Penelope M. Webb); Department of Epidemiology, Human Genetics, and Environmental Sciences, School of Public Health, University of Texas, Houston, Texas (Roberta B. Ness); Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina (Andrew Berchuck); Department of Oncology, Center for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, United Kingdom (Paul D. Pharoah); Department of Chronic Disease Epidemiology, School of Public Health, Yale University, New Haven, Connecticut (Harvey Risch); and Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan (Celeste Leigh Pearce). This work was supported by the National Cancer Institute, US National Institutes of Health (grant R01 CA076016), and the National Cancer Institute’s Genetic Associations and Mechanisms in Oncology (GAME‐ON) initiative (grant U19-CA148112). It was also supported by the National Institutes of Health (grants P30 CA14089, R01 CA61132, P01 CA17054, N01 PC67010, R03 CA113148, N01 CN025403, and R03 CA115195 (USC), K07 CA095666, R01 CA83918, K22 CA138563, and P30 CA072720 (NJO), R01 CA122443, P30 CA15083, and P50 CA136393R01 (MAY), R01 CA112523 and R01 CA87538 (DOV), R01 CA058860 (UCI), R01 CA063678, R01 CA074850, and R01 CA080742 (CON), R01 CA76016 (NCO), R01 CA54419 and P50 CA105009 (NEC), R01 CA61107 (MAL), and R01 CA095023, R01 CA126841, M01 RR000056, P50 CA159981, and K07 CA80668 (HOP)); the California Cancer Research Program (grants 0001389V20170 and 2110200 (USC)); the German Federal Ministry of Education and Research, Program of Clinical Biomedical Research (grant 01GB9401 (GER)); the German Cancer Research Centre (GER); the Danish Cancer Society (grant 94 222 52 (MAL)); Mermaid I (MAL); the Eve Appeal/ Oak Foundation (UKO); the Cancer Institute of New Jersey (NJO); the National Institute for Health Research University College London Hospitals Biomedical Research Centre (UKO); the US Army Medical Research and Materiel Command (grants W81XWH-10-1-02802 (NEC), DAMD17-02-1-0669 (HOP), DAMD17-02-1-0666 (NCO), and DAMD17-01-1-0729 (AUS)); the Roswell Park Alliance Foundation (HOP); the Cancer Councils of New South Wales, Victoria, Queensland, South Australia, and Tasmania (MultiState Application numbers 191, 211, and 182 (AUS)); the Cancer Foundation of Western Australia (AUS); the National Health and Medical Research Council of Australia (grants 199600 and 400281 (AUS)); the Mayo Foundation (MAY); the Minnesota Ovarian Cancer Alliance (MAY); the Fred C. and Katherine B. Andersen Foundation (MAY); Radboud University Medical Centre (NTH); the Lon V Smith Foundation (grant LVS-39420 (UCI)); the National Institute of Environmental Health Sciences, US National Institutes of Health (grant T32 ES013678 to A.W.L.); and the National Health and Medical Research Council of Australia (fellowship 1043134 to P.M.W.). (See Web Table 3 for definitions of parenthetical study abbreviations.) The research was also supported by the National Cancer Institute (grant P30 CA046592). Lastly, this work was also supported by the National Science Foundation (grant NSF DMS 1406712) and the National Institute of Environmental Health Sciences (grant NIH ES 20811). Funding Information: The Collaborative Oncological Gene-Environment Study is funded through the European Commission’s Seventh Framework Programme (agreement 223175 HEALTH F2 2009-223175). The Ovarian Cancer Association Consortium is supported by a grant from the Ovarian Cancer Research Fund thanks to donations by the family and friends of Kathryn Sladek Smith (grant PPD/RPCI.07). Publisher Copyright: © The Author(s) 2017. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved.
PY - 2018/2/1
Y1 - 2018/2/1
N2 - There have been recent proposals advocating the use of additive gene-environment interaction instead of the widely used multiplicative scale, as a more relevant public health measure. Using gene-environment independence enhances statistical power for testing multiplicative interaction in case-control studies. However, under departure from this assumption, substantial bias in the estimates and inflated type I error in the corresponding tests can occur. In this paper, we extend the empirical Bayes (EB) approach previously developed for multiplicative interaction, which trades off between bias and efficiency in a data-adaptive way, to the additive scale. An EB estimator of the relative excess risk due to interaction is derived, and the corresponding Wald test is proposed with a general regression setting under a retrospective likelihood framework. We study the impact of gene-environment association on the resultant test with case-control data. Our simulation studies suggest that the EB approach uses the gene-environment independence assumption in a data-adaptive way and provides a gain in power compared with the standard logistic regression analysis and better control of type I error when compared with the analysis assuming gene-environment independence. We illustrate the methods with data from the Ovarian Cancer Association Consortium.
AB - There have been recent proposals advocating the use of additive gene-environment interaction instead of the widely used multiplicative scale, as a more relevant public health measure. Using gene-environment independence enhances statistical power for testing multiplicative interaction in case-control studies. However, under departure from this assumption, substantial bias in the estimates and inflated type I error in the corresponding tests can occur. In this paper, we extend the empirical Bayes (EB) approach previously developed for multiplicative interaction, which trades off between bias and efficiency in a data-adaptive way, to the additive scale. An EB estimator of the relative excess risk due to interaction is derived, and the corresponding Wald test is proposed with a general regression setting under a retrospective likelihood framework. We study the impact of gene-environment association on the resultant test with case-control data. Our simulation studies suggest that the EB approach uses the gene-environment independence assumption in a data-adaptive way and provides a gain in power compared with the standard logistic regression analysis and better control of type I error when compared with the analysis assuming gene-environment independence. We illustrate the methods with data from the Ovarian Cancer Association Consortium.
KW - bias-variance tradeoff
KW - effect modification
KW - empirical Bayes estimation
KW - genetic risk score
KW - relative excess risk
KW - shrinkage
UR - http://www.scopus.com/inward/record.url?scp=85044296653&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85044296653&partnerID=8YFLogxK
U2 - 10.1093/aje/kwx243
DO - 10.1093/aje/kwx243
M3 - Article
C2 - 28633381
AN - SCOPUS:85044296653
SN - 0002-9262
VL - 187
SP - 366
EP - 377
JO - American Journal of Epidemiology
JF - American Journal of Epidemiology
IS - 2
ER -